** Brokerage H.C. Wainwright starts coverage of Corvus Pharmaceuticals with "buy" rating and PT of $11
** PT represents a 2x upside to stock's Tuesday close
** CRVS is testing its experimental drug, soquelitinib, a first-in-class ITK-specific inhibitor, for the treatment of both rare cancers and eczema, an autoimmune disease that causes red and itchy skin rashes
** Soquelitinib works by blocking the ITK enzyme, which is essential for T-cell activation, a type of white blood cells, reducing T-cell activity and controlling the immune response
** Brokerages says the drug "has potential in a variety of other disorders such as psoriasis, inflammatory bowel disease and allergic asthma"
** If late-stage study of the drug is successful, it could be approved in the U.S. by 2027, H.C. Wainwright says
** Brokerages forecasts soquelitinib to generate combined revenue of $801 mln by 2034
** Stock gained ~204% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.